Circulating blood biomarkers for Alzheimer’s and dementia, including plasma amyloid-β, phosphorylated tau (p-tau217, p-tau181), neurofilament light chain, and glial fibrillary acidic protein (GFAP), represent a rapidly advancing field with significant potential for minimally invasive early detection of dementia [50]. This evidence concerns the gene NEFL and dementia.